Lead Product(s) : Metformin
Therapeutic Area : Endocrinology
Study Phase : Undisclosed
Recipient : Elaine Chow
Deal Size : Inapplicable
Deal Type : Inapplicable
High FODMAP Diet With Metformin in preDM
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 28, 2022
Lead Product(s) : Metformin
Therapeutic Area : Endocrinology
Highest Development Status : Undisclosed
Recipient : Elaine Chow
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Metformin
Therapeutic Area : Endocrinology
Study Phase : Phase II
Recipient : Centre Hospitalier Universitaire, Amiens
Deal Size : Inapplicable
Deal Type : Inapplicable
May Metformin be Used in Renal Failure?
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 16, 2016
Lead Product(s) : Metformin
Therapeutic Area : Endocrinology
Highest Development Status : Phase II
Recipient : Centre Hospitalier Universitaire, Amiens
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Metformin
Therapeutic Area : Endocrinology
Study Phase : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Metformin Extended Release Versus Metformin Immediate Release in Subjects With Type 2 Diabetes
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 30, 2014
Lead Product(s) : Metformin
Therapeutic Area : Endocrinology
Highest Development Status : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Somatropin
Therapeutic Area : Endocrinology
Study Phase : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Saizen
Product Type : Hormone
Upfront Cash : Inapplicable
March 07, 2013
Lead Product(s) : Somatropin
Therapeutic Area : Endocrinology
Highest Development Status : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Somatropin
Therapeutic Area : Endocrinology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Hormone
Upfront Cash : Inapplicable
December 11, 2012
Lead Product(s) : Somatropin
Therapeutic Area : Endocrinology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Metformin
Therapeutic Area : Endocrinology
Study Phase : Phase IV
Sponsor : Merck Group
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 16, 2012
Lead Product(s) : Metformin
Therapeutic Area : Endocrinology
Highest Development Status : Phase IV
Sponsor : Merck Group
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Somatropin
Therapeutic Area : Endocrinology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Saizen® Solution for Injection Adult Growth Hormone Deficiency (GHD) Immunogenicity Study
Details : Undisclosed
Product Name : Undisclosed
Product Type : Hormone
Upfront Cash : Inapplicable
November 09, 2010
Lead Product(s) : Somatropin
Therapeutic Area : Endocrinology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Recombinant Human Growth Hormone
Therapeutic Area : Endocrinology
Study Phase : Phase IV
Sponsor : Merck Group
Deal Size : Inapplicable
Deal Type : Inapplicable
Predictive Markers in Chinese Growth Hormone Deficiency (GHD) Children Treated With Saizen®
Details : Undisclosed
Product Name : Undisclosed
Product Type : Hormone
Upfront Cash : Inapplicable
August 24, 2010
Lead Product(s) : Recombinant Human Growth Hormone
Therapeutic Area : Endocrinology
Highest Development Status : Phase IV
Sponsor : Merck Group
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Lutropin Alfa
Therapeutic Area : Endocrinology
Study Phase : Phase III
Sponsor : Merck Group
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
March 10, 2010
Lead Product(s) : Lutropin Alfa
Therapeutic Area : Endocrinology
Highest Development Status : Phase III
Sponsor : Merck Group
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Somatropin
Therapeutic Area : Endocrinology
Study Phase : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Hormone
Upfront Cash : Inapplicable
February 10, 2010
Lead Product(s) : Somatropin
Therapeutic Area : Endocrinology
Highest Development Status : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable